YY1-activated ZFPM2-AS1 promoted the malignant phenotypes of SCLC via sequestering miR-3612 to upregulate TRAF4, which possibly provide a promising candidate target for SCLC treatment. The gene discussed is ZFPM2; the disease is small cell lung carcinoma.